 Buprenorphine, Naloxone Drug Combination
"Buprenorphine, Naloxone Drug Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pharmaceutical preparation that combines buprenorphine, an OPIOID ANALGESIC with naloxone, a NARCOTIC ANTAGONIST to reduce the potential for NARCOTIC DEPENDENCE in the treatment of pain. It may also be used for OPIATE SUBSTITUTION THERAPY.
| Descriptor ID |
D000069479
|
| MeSH Number(s) |
D03.132.577.249.150.500 D03.132.577.249.706.275 D03.605.497.150.500 D03.605.497.750.275 D03.633.400.686.150.500 D03.633.400.686.750.275 D04.615.723.795.150.500 D04.615.723.795.706.275 D26.310.352
|
| Concept/Terms |
Buprenorphine, Naloxone Drug Combination- Buprenorphine, Naloxone Drug Combination
- Buprenorphine-Naloxone Drug Combination
- Combination, Buprenorphine-Naloxone Drug
- Drug Combination, Buprenorphine-Naloxone
- Buprenorphine-Naloxone
- Buprenorphine Naloxone
- Naloxone, Buprenorphine
- Buprenorphine-Naloxone Combination
- Buprenorphine Naloxone Combination
- Combination, Buprenorphine-Naloxone
- Buprenorphine Naloxone Drug Combination
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine, Naloxone Drug Combination".
- Chemicals and Drugs [D]
- Heterocyclic Compounds [D03]
- Alkaloids [D03.132]
- Opiate Alkaloids [D03.132.577]
- Morphinans [D03.132.577.249]
- Buprenorphine [D03.132.577.249.150]
- Buprenorphine, Naloxone Drug Combination [D03.132.577.249.150.500]
- Naloxone [D03.132.577.249.706]
- Buprenorphine, Naloxone Drug Combination [D03.132.577.249.706.275]
- Heterocyclic Compounds, Bridged-Ring [D03.605]
- Morphinans [D03.605.497]
- Buprenorphine [D03.605.497.150]
- Buprenorphine, Naloxone Drug Combination [D03.605.497.150.500]
- Naloxone [D03.605.497.750]
- Buprenorphine, Naloxone Drug Combination [D03.605.497.750.275]
- Heterocyclic Compounds, Fused-Ring [D03.633]
- Heterocyclic Compounds, 4 or More Rings [D03.633.400]
- Morphinans [D03.633.400.686]
- Buprenorphine [D03.633.400.686.150]
- Buprenorphine, Naloxone Drug Combination [D03.633.400.686.150.500]
- Naloxone [D03.633.400.686.750]
- Buprenorphine, Naloxone Drug Combination [D03.633.400.686.750.275]
- Polycyclic Compounds [D04]
- Polycyclic Aromatic Hydrocarbons [D04.615]
- Phenanthrenes [D04.615.723]
- Morphinans [D04.615.723.795]
- Buprenorphine [D04.615.723.795.150]
- Buprenorphine, Naloxone Drug Combination [D04.615.723.795.150.500]
- Naloxone [D04.615.723.795.706]
- Buprenorphine, Naloxone Drug Combination [D04.615.723.795.706.275]
- Pharmaceutical Preparations [D26]
- Drug Combinations [D26.310]
- Buprenorphine, Naloxone Drug Combination [D26.310.352]
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine, Naloxone Drug Combination".
This graph shows the total number of publications written about "Buprenorphine, Naloxone Drug Combination" by people in this website by year, and whether "Buprenorphine, Naloxone Drug Combination" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 2 | 0 | 2 | | 2019 | 1 | 1 | 2 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 2 | 2 | | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Buprenorphine, Naloxone Drug Combination" by people in Profiles.
-
Christine PJ, Lodi S, Hsu HE, Bovell-Ammon B, Yan S, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz J, Walley AY, Larochelle MR. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction. 2024 07; 119(7):1313-1321.
-
Wilson SC, Shaffer JA, Wachholtz AB. Distress Tolerance in the Comorbid Chronic Pain and Opioid Use Disorder Population. J Addict Med. 2023 May-Jun 01; 17(3):e164-e171.
-
Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Addiction. 2022 10; 117(10):2635-2648.
-
Mortaji P, Terasaki D, Moo-Young J. Advanced Inpatient Management of Opioid Use Disorder in a Patient Requiring Serial Surgeries. J Gen Intern Med. 2021 08; 36(8):2448-2451.
-
Knudsen HK, Lofwall MR, Lin LA, Walsh SL, Studts JL. US physicians' decision-making during buprenorphine-naloxone treatment: Conjoint analyses of dose and office visit adjustments based on patient progress. Drug Alcohol Depend. 2019 11 01; 204:107490.
-
Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. Int J Drug Policy. 2019 10; 72:160-168.
-
Barocas JA, Saitz R. Being Explicit About Decisions: Prescribe Medications for Opioid Use Disorder on the Basis of Proven Effectiveness, Not Beliefs. Ann Intern Med. 2019 01 15; 170(2):127-128.
-
Wang GS, Severtson SG, Bau GE, Dart RC, Green JL. Unit-Dose Packaging and Unintentional Buprenorphine-Naloxone Exposures. Pediatrics. 2018 06; 141(6).
-
Monte AA, Mandell T, Wilford BB, Tennyson J, Boyer EW. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis. 2009 Jul; 28(3):226-31.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|